KLRS — Kalaris Therapeutics, Inc.

Materials · Biological Products, (No Diagnostic Substances) · Nasdaq

CIK 0001754068 · FYE 1231 · All Form 4 filings on EDGAR ↗

Formerly: Allovir, Inc. (until 2025-03-12); ViraCyte, Inc. (until 2018-10-02)

1Insiders filing

1Transactions

+$0Reported buys

−$0Reported sells

0Cluster events

Window in data: 2026-08-27 → 2026-08-27 · Data as of 2026-08-31

Insiders

Insider	Role	Txns	Reported value
Vandekop Amy O'Leary	VP, Corporate Controller	1	$0

Transaction history

Filing date	Trade date	Ticker	Insider	Type	Shares	Price	Value	Cluster
2026-08-28	2026-08-27	KLRS	Vandekop Amy O'Leary VP, Corporate Controller	A routine	10,000	—	—	—

Known data limitations

Form 4 lag: insiders have 2 business days to file after a trade (weekends and holidays extend this), and this site re-ingests once daily — a transaction can appear here roughly three business days after it happened.

13F lag: quarterly 13F-HR holdings cover the prior quarter-end and are due 45 days after it — every institutional position shown here is at least 45 days old by construction, often more.

CUSIP→ticker gaps: 13F positions are reported by CUSIP; some holdings cannot be matched to a current ticker (delistings, corporate actions, thin metadata) and appear without one or are omitted from ticker-level views.

EDGAR timing variability: institutions file at different hours and days within their windows; amended filings (4/A, 13F-HR/A) can restate earlier periods, so historical aggregates may change between batches.

Insider Atlas is a descriptive research site, not investment advice — see the methodology for the full provenance chain.